Abiraterone in prostate cancer: a new angle to an old problem - Wikidata - awgldk - TriplyDB

Abiraterone in prostate cancer: a new angle to an old problem

Abiraterone in prostate cancer: a new angle to an old problem

http://www.wikidata.org/entity/Q26828810

about

The expression and prognostic significance of retinoic acid metabolising enzymes in colorectal cancer Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born.Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer Combination of α-Tomatine and Curcumin Inhibits Growth and Induces Apoptosis in Human Prostate Cancer Cells Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen.BET bromodomain inhibitors--a novel epigenetic approach in castration-resistant prostate cancer.Minireview: Androgen metabolism in castration-resistant prostate cancer.A hormone-DNA repair circuit governs the response to genotoxic insult Advances in androgen receptor targeted therapy for prostate cancer Combination of Lipitor and Celebrex inhibits prostate cancer VCaP cells in vitro and in vivo.Inhibition of IL-6 expression in LNCaP prostate cancer cells by a combination of atorvastatin and celecoxib.Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer.Copper signaling axis as a target for prostate cancer therapeutics.Prostate cancer: beware of disseminated intravascular coagulation.Discovery of the Selective CYP17A1 Lyase Inhibitor BMS-351 for the Treatment of Prostate Cancer.Luteolin, ellagic acid and punicic acid are natural products that inhibit prostate cancer metastasis.Ruthenium-containing P450 inhibitors for dual enzyme inhibition and DNA damage.Brefeldin A enhances docetaxel-induced growth inhibition and apoptosis in prostate cancer cells in monolayer and 3D cultures.Advanced prostate cancer--a case for adjuvant differentiation therapy.The differential expression of omega-3 and omega-6 fatty acid metabolising enzymes in colorectal cancer and its prognostic significance.Dual silencing of Hsp27 and c-FLIP enhances doxazosin-induced apoptosis in PC-3 prostate cancer cells.Y08060: A Selective BET Inhibitor for Treatment of Prostate Cancer.

P2860

Q21090644-D38D807B-9A68-4407-BD3B-FBE27451E6FC Q34291736-DF213713-DF91-47FF-9565-38BBA547F557 Q34416771-339675F4-F103-4919-AF32-E6B0C0D539FF Q35858905-AE4816C4-909A-43E6-8884-44C613DF61CB Q36029539-2FFAC0FA-95F5-4261-B706-1A58415BE431 Q36211507-0BF5D1C2-7025-4D0B-B318-D6480A5C490A Q36789277-EA8EF1AC-352B-4593-99F9-36CCF70FB907 Q37297350-D216AFDE-1B8A-4C9B-8C8A-825B8605259F Q37337217-90E9E56D-6715-4EC9-B5F8-BD4CB913553F Q37596358-4B0F27BF-EA7F-43F3-95E7-A45C045B5ECA Q37694029-9CCC9542-EC27-4CB0-AC65-A0E4CB2FFC51 Q38183819-18B31ADF-421B-426C-947C-F83AAD06FFB0 Q38947366-4755B2EA-A97B-4768-8A73-8E4F7C5F2AFC Q39265656-E72965CA-87C7-4EA1-878B-8E732FE4BEB6 Q43083930-C6427651-39AE-4C5F-8793-DF9AE0E949FB Q46369078-A010401C-8ADE-42D3-A169-6D6704DBB279 Q48313390-D0C965F6-4D83-4B1F-BF37-B43CFC3AFD50 Q50893407-EE62D776-6ADF-4C7B-BDEA-C3264FDEC639 Q50920040-B6D213E2-EFF4-4AE4-A955-3A26CA85F2CC Q50971441-73C1C265-4A59-4E1B-83B5-40FFFFA1D6C8 Q51797974-1A101157-E60A-46D9-9CAC-6EAE997A09BF Q53701939-FBAA686E-25E4-419D-A84C-099CBF4C952B

P2860

Abiraterone in prostate cancer: a new angle to an old problem

http://www.wikidata.org/entity/Q26828810

description

2012 nî lūn-bûn

@nan

2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Abiraterone in prostate cancer: a new angle to an old problem

@ast

Abiraterone in prostate cancer: a new angle to an old problem

@en

Abiraterone in prostate cancer: a new angle to an old problem

@nl

type

label

Abiraterone in prostate cancer: a new angle to an old problem

@ast

Abiraterone in prostate cancer: a new angle to an old problem

@en

Abiraterone in prostate cancer: a new angle to an old problem

@nl

prefLabel

Abiraterone in prostate cancer: a new angle to an old problem

@ast

Abiraterone in prostate cancer: a new angle to an old problem

@en

Abiraterone in prostate cancer: a new angle to an old problem

@nl

P1433

Q26828810-D5373FD9-C29E-404C-97DF-8E35FC59151E

P1476

Q26828810-AB798078-7BD8-4AE3-AE04-1AE075F134F0

P2093

Q26828810-4DEC91FE-04CE-4ADE-989D-15AF4D329CF2

Q26828810-719C80B0-3231-486B-9B62-C5CFD0C12D65

Q26828810-8EFCC989-926B-4257-9A1A-E086577E4FBD

P2860

Q26828810-15883103-1CAD-4FB4-A656-7E81A2582325

Q26828810-200BDBAC-EDC1-4E4E-9D5C-7F2C68AAF536

Q26828810-21DE4B5D-BE00-41AC-9E7C-2CD8BBD4BCC8

Q26828810-29685A02-979C-42B8-A5BD-7B96721ADE66

Q26828810-2AB0F1AB-2B05-4EF3-9D81-D4F51F85584C

Q26828810-2E4A8BAC-D0DD-425B-92CF-0663D3849132

Q26828810-31AA352E-0205-4C9F-8243-EB821A34B94D

Q26828810-3997E915-5C2B-48AE-A351-1448D0CD847D

Q26828810-46768E3C-9A81-451C-9D85-06235CEA0CCB

Q26828810-50C18BE5-7A82-450F-8C19-AD087FE8B9F7

P304

Q26828810-31105F8B-67AF-40BD-8762-272BDB600B36

P31

Q26828810-D96AC2E9-CD1F-46C4-86D4-49B98C6566FE

P3181

Q26828810-497B4D88-E031-4B72-B047-127E6DA0CCD4

P356

Q26828810-23A400CF-ED7C-4FA4-BA9A-A2F85EC0839C

P407

Q26828810-916D65DD-EA6A-41DC-B753-7DCAEE06AFEC

P433

Q26828810-3D0F011A-71DF-4985-B360-A7F39D99695D

P478

Q26828810-8E23DBED-B246-4BE3-9DCC-B62972695799

P577

Q26828810-76848AB2-7660-4561-9424-046662A6CCC0

P698

Q26828810-1D9210CE-BFEB-4C82-A799-9F49FEE0A98E

P921

Q26828810-1908E413-5312-4623-AB82-DEAC7B2F80BD

P932

Q26828810-5565F2D9-AEB5-4480-AC44-EDE69C118C9F

P3181

P356

1078-0432.CCR-11-1805

P1433

Clinical Cancer Research

P1476

Abiraterone in prostate cancer: a new angle to an old problem

@en

P2093

M. N. Stein

http://www.w3.org/2001/XMLSchema#string

R. S. DiPaola

http://www.w3.org/2001/XMLSchema#string

S. Goodin

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer

Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer

Abiraterone and increased survival in metastatic prostate cancer

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer

Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.

Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.

Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate

P304

1848-54

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1375157

http://www.w3.org/2001/XMLSchema#string

P356

10.1158/1078-0432.CCR-11-1805

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2012-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22451619

http://www.w3.org/2001/XMLSchema#string

P921

P932

3761800

http://www.w3.org/2001/XMLSchema#string